Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Page 1
Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA.
Hansen BE, Vandriel SM, Vig P, Garner W, Mogul DB, Loomes KM, Piccoli DA, Rand EB, Jankowska I, Czubkowski P, Gliwicz-Miedzińska D, Gonzales EM, Jacquemin E, Bouligand J, D'Antiga L, Nicastro E, Arnell H, Fischler B, Sokal É, Demaret T, Siew S, Stormon M, Karpen SJ, Romero R, Ebel NH, Feinstein JA, Roberts AJ, Evans HM, Sundaram SS, Chaidez A, Hardikar W, Shankar S, Fischer RT, Lacaille F, Debray D, Lin HC, Jensen MK, Jaramillo C, Karthikeyan P, Indolfi G, Verkade HJ, Larson-Nath C, Quiros-Tejeira RE, Valentino PL, Rogalidou M, Dezsőfi A, Squires JE, Schwarz K, Calvo PL, Bernabeu JQ, Zizzo AN, Nebbia G, Bulut P, Santos-Silva E, Fawaz R, Nastasio S, Karnsakul W, Tamara ML, Busoms CM, Kelly DA, Sandahl TD, Jimenez-Rivera C, Banales JM, Mujawar Q, Li LT, She H, Wang JS, Kim KM, Oh SH, Sanchez MC, Cavalieri ML, Lee WS, Hajinicolaou C, Lertudomphonwanit C, Waisbourd-Zinman O, Arikan C, Alam S, Carvalho E, Melere M, Eshun J, Önal Z, Desai DM, Wiecek S, Pinto RB, Wolters VM, Garcia J, Beretta M, Kerkar N, Brecelj J, Rock N, Lurz E, Blondet N, Shah U, Thompson RJ, Kamath BM; Global ALagille Alliance (GALA) Study Group. Hansen BE, et al. Among authors: evans hm. Hepatology. 2023 Dec 25. doi: 10.1097/HEP.0000000000000727. Online ahead of print. Hepatology. 2023. PMID: 38146932
Maralixibat, an ileal bile acid transporter inhibitor, is an approved pharmacologic therapy for cholestatic pruritus in ALGS. Since long-term placebo-controlled studies are not feasible or ethical in children with rare diseases, a novel approach was taken comparing 6-year …
Maralixibat, an ileal bile acid transporter inhibitor, is an approved pharmacologic therapy for cholestatic pruritus in ALGS. Since long- …
Long-term outcomes of liver transplantation for homozygous familial hypercholesterolaemia in Australia and New Zealand.
Page MM, Hardikar W, Alex G, Bates S, Srinivasan S, Stormon M, Hall K, Evans HM, Johnston P, Chen J, Wigg A, John L, Ekinci EI, O'Brien RC, Jones R, Watts GF. Page MM, et al. Among authors: evans hm. Atherosclerosis. 2023 Dec;387:117305. doi: 10.1016/j.atherosclerosis.2023.117305. Epub 2023 Oct 10. Atherosclerosis. 2023. PMID: 37863699
Newer drugs including lomitapide and evinacumab might reduce the need for apheresis and LT. We sought to determine the long-term outcomes following LT in Australia and New Zealand. METHODS: We analysed demographic, biochemical and clinical data from all patients in Austral …
Newer drugs including lomitapide and evinacumab might reduce the need for apheresis and LT. We sought to determine the long-term outc …
Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study.
C-MORE/PHOSP-COVID Collaborative Group. C-MORE/PHOSP-COVID Collaborative Group. Lancet Respir Med. 2023 Nov;11(11):1003-1019. doi: 10.1016/S2213-2600(23)00262-X. Epub 2023 Sep 22. Lancet Respir Med. 2023. PMID: 37748493 Free PMC article.
INTERPRETATION: After hospitalisation for COVID-19, people are at risk of multiorgan abnormalities in the medium term. Our findings emphasise the need for proactive multidisciplinary care pathways, with the potential for imaging to guide surveillance frequency and therapeu …
INTERPRETATION: After hospitalisation for COVID-19, people are at risk of multiorgan abnormalities in the medium term. Our findings e …
The Impact of Cybervictimization on the Self-Management of Chronic Conditions: Lived Experiences.
Alhaboby ZA, Evans H, Barnes J, Short E. Alhaboby ZA, et al. Among authors: evans h. J Med Internet Res. 2023 Aug 25;25:e40227. doi: 10.2196/40227. J Med Internet Res. 2023. PMID: 37624637 Free PMC article.
BACKGROUND: Cybervictimization of people with long-term conditions is a disturbing phenomenon with a documented impact on health and well-being. ...OBJECTIVE: This study aims to understand the impact of cybervictimization on the self-management of long-term conditio …
BACKGROUND: Cybervictimization of people with long-term conditions is a disturbing phenomenon with a documented impact on health and …
Factors associated with recurrent appendicitis after successful treatment with antibiotics.
Flum DR; writing group for the CODA Collaborative. Flum DR, et al. Br J Surg. 2023 Oct 10;110(11):1482-1489. doi: 10.1093/bjs/znad218. Br J Surg. 2023. PMID: 37459231
CONCLUSION: Most factors commonly associated with appendicitis severity were not strongly associated with an increased risk of undergoing appendicectomy in the longer term after treatment with antibiotics....
CONCLUSION: Most factors commonly associated with appendicitis severity were not strongly associated with an increased risk of undergoing ap …
Cybervictimization of Adults With Long-term Conditions: Cross-sectional Study.
Alhaboby ZA, Barnes J, Evans H, Short E. Alhaboby ZA, et al. Among authors: evans h. J Med Internet Res. 2023 May 17;25:e39933. doi: 10.2196/39933. J Med Internet Res. 2023. PMID: 37195761 Free PMC article.
However, the scope of such experiences is not well documented among adults with long-term conditions, and the potential impact has not been examined from a public health perspective. OBJECTIVE: This study aimed to examine the scope of cybervictimization among adults living …
However, the scope of such experiences is not well documented among adults with long-term conditions, and the potential impact has no …
Long-term Outcome of Asymptomatic Patients With Graft Fibrosis in Protocol Biopsies After Pediatric Liver Transplantation.
Hartleif S, Hodson J, Lloyd C, Cousin VL, Czubkowski P, D'Antiga L, Debray D, Demetris A, Di Giorgio A, Evans HM, Fischler B, Gonzales E, Gouw ASH, Hübscher SG, Jacquemin E, Lacaille F, Malenicka S, McLin VA, Markiewicz-Kijewska M, Mazariegos GV, Rajanayagam JK, Scheenstra R, Singer S, Smets F, Sokal E, Squires JE, Sturm E, Verkade H, Kelly DA; Graft Injury Group (GIG). Hartleif S, et al. Among authors: evans hm. Transplantation. 2023 Nov 1;107(11):2394-2405. doi: 10.1097/TP.0000000000004603. Epub 2023 Oct 21. Transplantation. 2023. PMID: 37143195
BACKGROUND: The histological prevalence of allograft fibrosis in asymptomatic children after liver transplantation (LT) is well documented. However, long-term graft and patient survival remain unclear. This retrospective multicenter study aims to determine the prevalence o …
BACKGROUND: The histological prevalence of allograft fibrosis in asymptomatic children after liver transplantation (LT) is well documented. …
Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study.
Jackson C, Stewart ID, Plekhanova T, Cunningham PS, Hazel AL, Al-Sheklly B, Aul R, Bolton CE, Chalder T, Chalmers JD, Chaudhuri N, Docherty AB, Donaldson G, Edwardson CL, Elneima O, Greening NJ, Hanley NA, Harris VC, Harrison EM, Ho LP, Houchen-Wolloff L, Howard LS, Jolley CJ, Jones MG, Leavy OC, Lewis KE, Lone NI, Marks M, McAuley HJC, McNarry MA, Patel BV, Piper-Hanley K, Poinasamy K, Raman B, Richardson M, Rivera-Ortega P, Rowland-Jones SL, Rowlands AV, Saunders RM, Scott JT, Sereno M, Shah AM, Shikotra A, Singapuri A, Stanel SC, Thorpe M, Wootton DG, Yates T, Gisli Jenkins R, Singh SJ, Man WD, Brightling CE, Wain LV, Porter JC, Thompson AAR, Horsley A, Molyneaux PL, Evans RA, Jones SE, Rutter MK, Blaikley JF; PHOSP-COVID Study Collaborative Group. Jackson C, et al. Lancet Respir Med. 2023 Aug;11(8):673-684. doi: 10.1016/S2213-2600(23)00124-8. Epub 2023 Apr 15. Lancet Respir Med. 2023. PMID: 37072018 Free PMC article.
Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study.
McAuley HJC, Evans RA, Bolton CE, Brightling CE, Chalmers JD, Docherty AB, Elneima O, Greenhaff PL, Gupta A, Harris VC, Harrison EM, Ho LP, Horsley A, Houchen-Wolloff L, Jolley CJ, Leavy OC, Lone NI, Man WD, Marks M, Parekh D, Poinasamy K, Quint JK, Raman B, Richardson M, Saunders RM, Sereno M, Shikotra A, Singapuri A, Singh SJ, Steiner M, Tan AL, Wain LV, Welch C, Whitney J, Witham MD, Lord J, Greening NJ; PHOSP-COVID Study Collaborative Group. McAuley HJC, et al. EClinicalMedicine. 2023 Mar 11;57:101896. doi: 10.1016/j.eclinm.2023.101896. eCollection 2023 Mar. EClinicalMedicine. 2023. PMID: 36936404 Free PMC article.
BACKGROUND: The scale of COVID-19 and its well documented long-term sequelae support a need to understand long-term outcomes including frailty. ...
BACKGROUND: The scale of COVID-19 and its well documented long-term sequelae support a need to understand long-term outcomes i …
Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma.
Fan R, Satilmis H, Vandewalle N, Verheye E, Vlummens P, Maes A, Muylaert C, De Bruyne E, Menu E, Evans H, Chantry A, De Beule N, Hose D, Törngren M, Eriksson H, Vanderkerken K, Maes K, Breckpot K, De Veirman K. Fan R, et al. Among authors: evans h. J Immunother Cancer. 2023 Jan;11(1):e005319. doi: 10.1136/jitc-2022-005319. J Immunother Cancer. 2023. PMID: 36650020 Free PMC article.
Tasquinimod-mediated targeting of the myeloid cell population resulted in increased T cell proliferation and functionality in vitro. Notably, short-term tasquinimod therapy of 5TMM mice significantly increased the total CD11b(+) cells and shifted this population toward a m …
Tasquinimod-mediated targeting of the myeloid cell population resulted in increased T cell proliferation and functionality in vitro. Notably …
92 results